Loading...

VENUSREM Venus Remedies Ltd Other Special Situation Announcement

Vns

VNSR

Venus Remedies Ltd

(VENUSREM)

2025 Announcement

Share transfer window

SEBI circular relodgement

License milestones

Income Tax Matters

Special transfer window

Volume spike clarification

Regulatory disclosure

Newspaper Publication

Financial Results Update

Board Meeting Outcome

Share Transfer Window

Board Meeting Notice

SEBI Circular Update

Re-lodgement Window

Compliance Confirmation

Share Transfer Window

Share Transfer Re-lodgement

Social Media Campaign

Share Transfer Window

Share Transfer Window

Re-lodgement Window

Saksham Niveshak Campaign

Share Transfer Re-lodgement

Newspaper Publication

Finance Results Publication

Transfer Requests Update

AGM Notice Published

AGM Notice Published

Compliance Certificate

Financial Results Published

Management Changes

GMP Certification Renewed

Compliance Report

Email Address Change

FDA Designation Granted

SEBI Compliance Confirmation

Exclusive Rights Secured

Market Authorization Granted

Financial Results Published

Liability Write-Off

SEBI Compliance Confirmation

Market Expansion

SOP Fine Payment

Marketing Authorization Sec...

Expansion in Hungary

GMP Approval Achieved

Financial Results Published

Regulatory Compliance

Director Retirements

Management Changes

Annual General Meeting

Book Closure Notice

AGM Notice Issued

Financial Results

Management Change

Tax Case Resolution

Compliance Certificate Subm...

Global Fight Against Cancer

UNICEF Award Achievement

Financial Results Publication

Compliance Report Submission

Confirmation Certificate Su...

Compliance Certificate Subm...

Compliance Certificate

PLI Incentive Awarded

Award of Incentive

Approval from UNICEF

Marketing Approval

VENUS REMEDIES LTD.

Newspaper Publication

Marketing Authorizations

GMP Certification

Marketing Authorizations Se...

Achievements in marketing a...

Venus Remedies Ltd. Transfo...

New Marketing Authorizations

Fined for omission of finan...

Market Authorizations Granted

Marketing Authorizations in...

Financial Results Publication

Export House Certificate

FICCI Healthcare Award 2023

market authorization

REO Certification

ASEAN expansion

Global Expansion

Compliance Confirmation Cer...

Award Announcement

Oncology Portfolio Expansion

DSIR Registration for Custo...

Expansion in Gulf

Equity, Debt, VC, Private E...

Financial Statements

Trading Restriction Update

Financial Statements

Financial Statements

Management Changes

Asset Acquisitions

Foreign Investment

Financial Results Publication

Regulatory Compliance

Increase in recognition

External Links:

Data:

Venus Remedies Ltd's investigational product VRP-034 has received Qualified Infectious Disease Product designation from the US FDA, aimed at treating bloodstream infections with a 70% reduction in nephrotoxicity compared to conventional treatments, as announced on April 17, 2025.

AI Assistant

Venus Remedies Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.